News

Novo Nordisk Gains as CFO Touts Wegovy’s Rebound Potential
Novo Nordisk A/S shares gained on expectations that competition for its blockbuster obesity shot Wegovy will subside later ...
Novo Nordisk Strikes $2.2 Billion Deal With Septerna to Develop New Obesity Treatments
COPENHAGEN (Reuters) -Novo Nordisk has struck a collaboration and licensing deal with U.S. biotech Septerna to develop oral ...
Ignore The Noise - Novo Nordisk Is A Clear Buy
Novo Nordisk's current product portfolio is well-protected by patents until at least 2030. Click here to see why NVO stock is ...
Currency hedging and new U.S. factories: Novo Nordisk CFO thinks Wegovy maker can outmaneuver global trade wars
Novo Nordisk is hedging and building its way around a global tariff war that may threaten the Wegovy maker’s plans to expand ...
NBC Bay Area9d
Novo Nordisk shares pop as drugmaker sees copycat Wegovy sales easing in 2025
Shares of Novo Nordisk jumped nearly 7% on Wednesday after it said sales of its blockbuster Wegovy weight loss drug were seen improving in the second half of the year as the availability of ...
GlobalData on MSN8d
Novo Nordisk cuts 2025 outlook due to compounding-hit Wegovy demand
Shares in Novo Nordisk were still up after Q1 2025 witnessed a total revenue jump by 18%, compared to Q1 2024.
Explore more
Novo Nordisk Says FDA Accepted New Drug Application for Wegovy Pill
The Bagsvaerd, Denmark, company said that if the application is approved, Wegovy would become the first oral formulation of a ...
This biotech’s stock rockets on oral obesity-drug partnership with Wegovy parent
Wednesday trading after the biotech clinched a partnership with Wegovy and Ozempic parent Novo Nordisk to collaborate on oral ...